Table 2.
Baseline characteristics for patients with different glycemic metabolism status
| Variables | Total (n = 6140) | NG (n = 1394) | Pre-DM (n = 2884) | DM (n = 1862) | P value |
|---|---|---|---|---|---|
| Age, years | 58.4 ± 10.4 | 55.9 ± 10.8 | 58.9 ± 10.4 | 59.4 ± 9.8 | < 0.001 |
| Male, % | 4771 (77.7) | 1138(81.6) | 2224(77.1) | 1409(75.7) | < 0.001 |
| BMI, kg/m2 | 25.9 ± 3.2 | 25.7 ± 3.1 | 25.8 ± 3.2 | 26.2 ± 3.2 | < 0.001 |
| Hypertension, % | 3930 (64.0) | 830(59.5) | 1791(62.1) | 1309(70.3) | < 0.001 |
| Dyslipidemia, % | 4241 (69.1) | 906(65.0) | 1910(66.2) | 1425(76.5) | < 0.001 |
| Family history of CAD, % | 1433 (23.3) | 355(25.5) | 653(22.6) | 425(22.8) | 0.101 |
| Smoking, % | 3496 (56.9) | 810(58.1) | 1664(57.7) | 1022(54.9) | 0.098 |
| Prior MI, % | 1219 (19.9) | 265(19.0) | 567(19.7) | 387(20.8) | 0.426 |
| Prior PCI or CABG, % | 1581 (25.7) | 322(23.1) | 729(25.3) | 530(28.5) | 0.002 |
| Prior stroke, % | 658 (10.7) | 130(9.3) | 279(9.7) | 249(13.4) | < 0.001 |
| Clinical presentation, % | < 0.001 | ||||
| SAP | 2572 (41.9) | 537 (38.5) | 1193 (41.4) | 842 (45.2) | |
| ACS | 3568 (58.1) | 857 (61.5) | 1691 (58.6) | 1020 (54.8) | |
| LVEF, % | 63.0 ± 7.2 | 63.0 ± 7.2 | 63.3 ± 7.1 | 62.6 ± 7.4 | < 0.001 |
| FBG, mmol/L | 6.1 ± 2.0 | 4.7 ± 0.4 | 5.2 ± 0.6 | 7.3 ± 2.5 | 0.009 |
| HbA1c, % | 6.6 ± 1.2 | 5.4 ± 0.2 | 6.0 ± 0.2 | 7.5 ± 1.3 | < 0.001 |
| FIB, mg/dL | 3.40 ± 0.84 | 3.32 ± 0.85 | 3.39 ± 0.85 | 3.47 ± 0.82 | < 0.001 |
| hs-CRP, mg/L | 3.14 ± 3.77 | 3.06 ± 3.82 | 3.11 ± 3.71 | 3.26 ± 3.82 | 0.260 |
| D-dimer, μg/mL | 0.41 ± 0.65 | 0.38 ± 0.50 | 0.42 ± 0.65 | 0.42 ± 0.73 | 0.376 |
| TC, mmol/L | 4.17 ± 1.09 | 4.18 ± 1.10 | 4.21 ± 1.08 | 4.10 ± 1.10 | 0.004 |
| HDL-C, mmol/L | 1.02 ± 0.28 | 1.01 ± 0.28 | 1.04 ± 0.28 | 0.99 ± 0.27 | < 0.001 |
| LDL-C, mmol/L | 2.48 ± 0.92 | 2.50 ± 0.94 | 2.51 ± 0.92 | 2.41 ± 0.90 | 0.001 |
| TG, mmol/L | 1.81 ± 1.12 | 1.78 ± 1.09 | 1.75 ± 0.94 | 1.92 ± 1.37 | < 0.001 |
| Creatinine (μmol/L) | 75.4 ± 16.0 | 75.6 ± 15.9 | 75.5 ± 15.2 | 75.0 ± 17.3 | 0.485 |
| Lesion vessels | 1.4 ± 0.7 | 1.4 ± 0.6 | 1.4 ± 0.7 | 1.5 ± 0.7 | < 0.001 |
| LM/three-vessel disease, % | 2773 (45.2) | 567 (40.7) | 1224 (42.4) | 982 (52.7) | < 0.001 |
| SYNTAX scorea | 12.0 ± 8.2 | 11.7 ± 7.9 | 11.7 ± 8.1 | 12.6 ± 8.5 | 0.001 |
| Complete revascularization, % | 3310 (53.9) | 798 (57.2) | 1646 (57.1) | 866 (46.5) | < 0.001 |
| Number of stents | 1.8 ± 1.2 | 1.8 ± 1.1 | 1.8 ± 1.1 | 1.9 ± 1.3 | 0.028 |
| DES implantation, % | 5778 (94.1) | 1323 (94.9) | 2730 (94.7) | 1725 (92.6) | 0.006 |
| Medications at discharge, % | |||||
| Aspirin | 6077 (99.0) | 1372(98.4) | 2859(99.1) | 1846(99.1) | 0.067 |
| Clopidogrel | 6020 (98.0) | 1366(98.0) | 2827(98.0) | 1827(98.1) | 0.959 |
| β-blocker | 5609 (91.4) | 1250(89.7) | 2622(90.9) | 1737(93.3) | 0.001 |
| ACEI/ARB | 3150 (51.3) | 697(50.0) | 1396(48.4) | 1057(56.8) | < 0.001 |
| CCB | 2875 (46.8) | 604(43.3) | 1341(46.5) | 930(49.9) | 0.001 |
| Statin | 5923 (96.5) | 1332(95.6) | 2801(97.1) | 1790(96.1) | 0.022 |
| Nitrate | 5984 (97.5) | 1358(97.4) | 2820(97.8) | 1806(97.0) | 0.240 |
Values are presented as mean ± standard deviation or number (%)
ACEI angiotensin-converting enzyme inhibitors, ACS acute coronary syndrome, ARB angiotensin II receptor blockers, BMI body mass index, CAD coronary artery disease, CABG coronary artery bypass grafting, CCB calcium channel blocker, DES drug-eluting stent, FIB fibrinogen, FBG fasting blood glucose, hs-CRP high sensitivity C-reactive protein, HbA1c Hemoglobin A1c, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LM left main disease, LVEF left ventricular ejection fraction, MI myocardial infarction, PCI percutaneous coronary intervention, SAP stable angina pectoris, TC total cholesterol, TG triglycerides
aCalculated using an online calculator (http://www.syntaxscore.com/) by a dedicated research group blinded to the clinical data